Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.42 Average PT from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average rating of “Buy” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $49.91.

A number of brokerages have issued reports on DYN. Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Robert W. Baird initiated coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Finally, Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th.

Dyne Therapeutics Trading Down 2.7 %

NASDAQ:DYN opened at $24.76 on Monday. The business’s fifty day moving average price is $27.78 and its 200 day moving average price is $34.42. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -6.96 and a beta of 1.16. Dyne Therapeutics has a 1-year low of $14.29 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities analysts forecast that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at $5,671,382.20. This represents a 1.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,742 shares of company stock worth $1,443,246 over the last ninety days. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in Dyne Therapeutics by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock valued at $3,655,000 after acquiring an additional 4,236 shares in the last quarter. Virtue Capital Management LLC raised its stake in shares of Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock valued at $834,000 after purchasing an additional 981 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Dyne Therapeutics by 4.8% in the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after purchasing an additional 84,760 shares in the last quarter. Barclays PLC boosted its stake in Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock worth $7,446,000 after buying an additional 128,246 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Dyne Therapeutics during the third quarter worth $1,067,000. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.